1
|
Engelhardt PM, Strippel J, Albat D, Chiha S, Rojas Pión J, Plein L, Kühne R, Müller M, Schmalz HG. C-Terminal Decarboxylation of Proline-Derived Building Blocks for Protein-Binding Peptides. Chemistry 2024; 30:e202401678. [PMID: 38770931 DOI: 10.1002/chem.202401678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 05/21/2024] [Accepted: 05/21/2024] [Indexed: 05/22/2024]
Abstract
Using a set of conformationally restricted Proline-derived Modules (ProMs), our group has recently succeeded in developing inhibitors for the enabled/vasodilator-stimulated phosphoprotein homology 1 (EVH1) domain, which is a key mediator of cell migration and plays an important role in tumor metastasis. While these (formally) pentapeptidic compounds show nanomolecular binding affinities towards EVH1, their drug-like properties and cell permeability need to be further optimized before they can be clinically tested as therapeutic agents against metastasis. In this study, we sought to improve these properties by removing the C-terminal carboxylic acid function of our peptoids, either by late-stage decarboxylation or by direct synthesis. For late-stage decarboxylation of ProM-like systems, a method for reductive halo decarboxylation was optimized and applied to several proline-derived substrates. In this way, a series of new decarboxy ProMs suitable as building blocks for decarboxy EVH1 inhibitors were obtained. In addition, we incorporated decarboxy-ProM-1 into the pentapeptide-like compound Ac[2ClF][ProM-2][Decarb-ProM-1], which showed similar affinity towards EVH1 as the methyl ester derivative (Ac[2Cl-F][ProM-2][ProM1]OMe). However, despite better calculated drug-like properties, this compound did not inhibit chemotaxis in a cellular assay.
Collapse
Affiliation(s)
- Pascal M Engelhardt
- University of Cologne, Department of Chemistry, Greinstraße 4, 50939, Cologne, Germany
| | - Julian Strippel
- University of Cologne, Department of Chemistry, Greinstraße 4, 50939, Cologne, Germany
| | - Dominik Albat
- University of Cologne, Department of Chemistry, Greinstraße 4, 50939, Cologne, Germany
- Prosion Therapeutics GmbH, Luxemburger Str. 90, 50939, Köln, Germany
| | - Slim Chiha
- Prosion Therapeutics GmbH, Luxemburger Str. 90, 50939, Köln, Germany
| | | | - Laura Plein
- University of Cologne, Department of Chemistry, Greinstraße 4, 50939, Cologne, Germany
| | - Ronald Kühne
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Matthias Müller
- Prosion Therapeutics GmbH, Luxemburger Str. 90, 50939, Köln, Germany
| | - Hans-Günther Schmalz
- University of Cologne, Department of Chemistry, Greinstraße 4, 50939, Cologne, Germany
| |
Collapse
|
2
|
Hernández-Benítez RI, Viveros-Ceballos JL, Ordoñez M, Labastida-Galván V. Stereocontrolled Synthesis of Phosphoproline Analogues Containing a trans-Fused Octahydroindole Bicyclic System. J Org Chem 2024; 89:4916-4922. [PMID: 38516706 DOI: 10.1021/acs.joc.4c00124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Herein we report for the first time the diastereoselective synthesis of (2R,3aR,7aS)- and (2S,3aS,7aR)-octahydroindole-2-phosphonic acid (OicP trans-fused stereoisomers) from diethyl (R)- and (S)-phosphopyroglutamate derivative. The key steps of this procedure are the ruthenium tetroxide oxidation of enantiomerically pure diethyl (R)- and (S)-phosphoprolinate obtained through Katritzky's benzotriazole-oxazolidine methodology, a highly diastereoselective successive double 4,5-diallylation of diethyl (R)- and (S)-phosphopyroglutamate with allyl bromide and allyltrimethylsilane with a trans-addition mode, and a ring-closing metathesis with Grubbs' first-generation ruthenium catalyst.
Collapse
Affiliation(s)
- R Israel Hernández-Benítez
- Centro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico
| | - José Luis Viveros-Ceballos
- Centro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico
| | - Mario Ordoñez
- Centro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico
| | - Victoria Labastida-Galván
- Centro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico
| |
Collapse
|
3
|
Novotná K, Tenora L, Prchalová E, Paule J, Alt J, Veeravalli V, Lam J, Wu Y, Šnajdr I, Gori S, Mettu VS, Tsukamoto T, Majer P, Slusher BS, Rais R. Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-l-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery. J Med Chem 2023; 66:15493-15510. [PMID: 37949450 PMCID: PMC10683027 DOI: 10.1021/acs.jmedchem.3c01681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 10/19/2023] [Accepted: 10/24/2023] [Indexed: 11/12/2023]
Abstract
The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) exhibits remarkable anticancer efficacy; however, its therapeutic potential is hindered by its toxicity to gastrointestinal (GI) tissues. We recently reported the discovery of DRP-104, a tumor-targeted DON prodrug with excellent efficacy and tolerability, which is currently in clinical trials. However, DRP-104 exhibits limited aqueous solubility, and the instability of its isopropyl ester promoiety leads to the formation of an inactive M1-metabolite, reducing overall systemic prodrug exposure. Herein, we aimed to synthesize DON prodrugs with various ester and amide promoieties with improved solubility, GI stability, and DON tumor delivery. Twenty-one prodrugs were synthesized and characterized in stability and pharmacokinetics studies. Of these, P11, tert-butyl-(S)-6-diazo-2-((S)-2-(2-(dimethylamino)acetamido)-3-phenylpropanamido)-5-oxo-hexanoate, showed excellent metabolic stability in plasma and intestinal homogenate, high aqueous solubility, and high tumor DON exposures and preserved the ideal tumor-targeting profile of DRP-104. In conclusion, we report a new generation of glutamine antagonist prodrugs with improved physicochemical and pharmacokinetic attributes.
Collapse
Affiliation(s)
- Kateřina Novotná
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
- Institute
of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences
of the Czech Republic, Prague 160 00, Czech Republic
- Department
of Organic Chemistry, Faculty of Science, Charles University, Prague 128 00, Czech Republic
| | - Lukáš Tenora
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
- Institute
of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences
of the Czech Republic, Prague 160 00, Czech Republic
| | - Eva Prchalová
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
- Institute
of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences
of the Czech Republic, Prague 160 00, Czech Republic
| | - James Paule
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Jesse Alt
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Vijay Veeravalli
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Jenny Lam
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Ying Wu
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Ivan Šnajdr
- Institute
of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences
of the Czech Republic, Prague 160 00, Czech Republic
| | - Sadakatali Gori
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Vijaya Saradhi Mettu
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Takashi Tsukamoto
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Pavel Majer
- Institute
of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences
of the Czech Republic, Prague 160 00, Czech Republic
| | - Barbara S. Slusher
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| | - Rana Rais
- Johns
Hopkins Drug Discovery, Departments of Neurology, Psychiatry and Behavioral Sciences, Pharmacology and
Molecular Sciences, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
| |
Collapse
|
4
|
Liu Z, Shi X, Shu W, Qi S, Wang X, He X. The effect of hydration and dehydration on the conformation, assembling behavior and photoluminescence of PBLG. SOFT MATTER 2022; 18:4396-4401. [PMID: 35635105 DOI: 10.1039/d2sm00344a] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Hydration and dehydration play crucial roles in hydrophobic effects (HEs) and are yet to be understood. Poly(γ-benzyl-L-glutamate) (PBLG) homopolymers in THF/water with various water contents were investigated. We discovered that PBLG was hydrated at low water contents and adopted a helical conformation. The chain became dehydrated with increasing water content, which converted the PBLG100 helix to a PPII-helix. The variation in the conformation resulted in an alteration of the self-assembled morphologies from fibers to particles. For PBLG12 with a shorter chain, the chain underwent an α-to-β transition in the conformation due to dehydration as the water content increased, and correspondingly the morphologies varied from tapes to helical ribbons, and eventually to toroids at a higher water content. We also observed that this α-to-β transition is accompanied by an increase in intensity of the fluorescence, which is attributed to the through-space-conjugation of tightly packed phenyl groups within the β-sheet. The discovered effect of hydration and dehydration on the PBLG chain conformation, self-assembling behavior and optical function is essential for the innovation of polypeptide materials and understanding of water-mediated biological systems.
Collapse
Affiliation(s)
- Zhen Liu
- School of Chemistry and Molecular Engineering, East China Normal University, No. 500 Dongchuan Road, shanghai 200241, China.
| | - Xinjie Shi
- School of Chemistry and Molecular Engineering, East China Normal University, No. 500 Dongchuan Road, shanghai 200241, China.
| | - Wenchao Shu
- School of Chemistry and Molecular Engineering, East China Normal University, No. 500 Dongchuan Road, shanghai 200241, China.
| | - Shuo Qi
- School of Chemistry and Molecular Engineering, East China Normal University, No. 500 Dongchuan Road, shanghai 200241, China.
| | - Xiaosong Wang
- Department of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, N21 3G1, Canada.
| | - Xiaohua He
- School of Chemistry and Molecular Engineering, East China Normal University, No. 500 Dongchuan Road, shanghai 200241, China.
| |
Collapse
|
5
|
Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells. Proc Natl Acad Sci U S A 2020; 117:29684-29690. [PMID: 33184177 PMCID: PMC7703624 DOI: 10.1073/pnas.2007213117] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Protein–protein interactions mediated by proline-rich motifs are involved in regulation of many important signaling cascades. These motifs belong to the most abundant recognition motifs in the eukaryotic genome and preferentially adopt a left-handed polyproline helix II, a secondary structure element that has been notoriously difficult to mimic with small molecules. Here, we present a structure-guided design effort yielding a toolkit of chemical entities that enables rational construction of selective small molecule inhibitors for these protein domains. We succeeded in developing an inhibitor for the Ena/VASP protein family that is active in vivo and reduces extravasation of invasive breast cancer cells in a zebrafish model. Battling metastasis through inhibition of cell motility is considered a promising approach to support cancer therapies. In this context, Ena/VASP-depending signaling pathways, in particular interactions with their EVH1 domains, are promising targets for pharmaceutical intervention. However, protein–protein interactions involving proline-rich segments are notoriously difficult to address by small molecules. Hence, structure-based design efforts in combination with the chemical synthesis of additional molecular entities are required. Building on a previously developed nonpeptidic micromolar inhibitor, we determined 22 crystal structures of ENAH EVH1 in complex with inhibitors and rationally extended our library of conformationally defined proline-derived modules (ProMs) to succeed in developing a nanomolar inhibitor (Kd=120 nM,MW=734 Da). In contrast to the previous inhibitor, the optimized compounds reduced extravasation of invasive breast cancer cells in a zebrafish model. This study represents an example of successful, structure-guided development of low molecular weight inhibitors specifically and selectively addressing a proline-rich sequence-recognizing domain that is characterized by a shallow epitope lacking defined binding pockets. The evolved high-affinity inhibitor may now serve as a tool in validating the basic therapeutic concept, i.e., the suppression of cancer metastasis by inhibiting a crucial protein–protein interaction involved in actin filament processing and cell migration.
Collapse
|